How much revenue does Shanghai Haixin Group make?

Shanghai Haixin Group reported 757.52 million CNY in revenue for fiscal year 2025, down 4.8% from 795.88 million CNY in fiscal year 2024. In Q1 2026 revenue was 150.42 million CNY.

What is Shanghai Haixin Group's largest business segment?

Medical, with 435.00 million CNY or 56% of segment revenue in fiscal year 2025. Next: Textile (17%) and Trade (13%).

Where does Shanghai Haixin Group make most of its revenue?

China: 82% of revenue by region in fiscal year 2025, followed by Overseas (18%).

What companies are similar to Shanghai Haixin Group?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS), Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ), Yifan Pharmaceutical Co., Ltd. (002019.SZ), Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS).

Shanghai Haixin Group Co., Ltd. (600851.SS) Stock

About Shanghai Haixin Group Co., Ltd.

Shanghai Haixin Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in China and internationally. It is also involved in leasing of industrial park properties, financial investment and commodity trading, as well as production and sales of chemical drugs through its sales platform or local distributors; and research and development, production, and sales of plush fabrics ...

At a glance

Shanghai Haixin Group reported revenue of 757.52 million CNY for fiscal year 2025, down 4.8% from fiscal year 2024, and net income of 176.00 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 150.42 million CNY, down 25.7% from a year before. Its largest business segment, Medical, brought in 56% of segment revenue in fiscal year 2025; China was the largest region with 82%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.